within Pharmacolibrary.Drugs.ATC.S;

model S03AA07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 42 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.12,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic used to treat a variety of bacterial infections including those of the urinary tract, respiratory tract, gastrointestinal system, skin, and eyes. It acts by inhibiting bacterial DNA gyrase and topoisomerase IV. Ciprofloxacin remains approved and widely used today for many infections sensitive to its action.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following a single oral dose.</p><h4>References</h4><ol><li><p>Junkert, AM, et al., &amp; Pontarolo, R (2024). Pharmacokinetics of oral ciprofloxacin in adult patients: A scoping review. <i>British journal of clinical pharmacology</i> 90(2) 528–547. DOI:<a href=&quot;https://doi.org/10.1111/bcp.15933&quot;>10.1111/bcp.15933</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37850318/&quot;>https://pubmed.ncbi.nlm.nih.gov/37850318</a></p></li><li><p>Tolentino-Hernández, SJ, et al., &amp; Castañeda-Hernández, G (2020). Oral Ciprofloxacin Pharmacokinetics in Healthy Mexican Volunteers and Other Populations: Is There Interethnic Variability?. <i>Archives of medical research</i> 51(3) 268–277. DOI:<a href=&quot;https://doi.org/10.1016/j.arcmed.2020.02.008&quot;>10.1016/j.arcmed.2020.02.008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32143939/&quot;>https://pubmed.ncbi.nlm.nih.gov/32143939</a></p></li><li><p>van Rhee, KP, et al., &amp; Knibbe, CAJ (2022). Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study. <i>Clinical pharmacokinetics</i> 61(8) 1167–1175. DOI:<a href=&quot;https://doi.org/10.1007/s40262-022-01130-5&quot;>10.1007/s40262-022-01130-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35641862/&quot;>https://pubmed.ncbi.nlm.nih.gov/35641862</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S03AA07;
